PSivida Announces New Safety And Efficacy Data From Phase 3 Study Of ILUVIEN(R) In Diabetic Macular Edema

Podiatry Arena PSivida Announces New Safety And Efficacy Data From Phase 3 Study Of ILUVIEN(R) In Diabetic Macular Edema

Welcome to the Podiatry Arena forums, for communication between foot health professionals about podiatry and related topics.

You are currently viewing our podiatry forum as a guest which gives you limited access to view all podiatry discussions and access our other features. By joining our free global community of Podiatrists and other interested foot health care professionals you will have access to post podiatry topics (answer and ask questions), communicate privately with other members (PM), upload content, view attachments, receive a weekly email update of new discussions, earn CPD points and access many other special features. Registered users do not get displayed the advertisments in posted messages. Registration is fast, simple and absolutely free so please, join our global Podiatry community today!

If you have any problems with the registration process or your account login, please contact contact us.

PSivida Announces New Safety And Efficacy Data From Phase 3 Study Of ILUVIEN(R) In Diabetic Macular Edema

Submit Thread >

< Submit Thread

Thread Tools

Display Modes

4th May 2011, 06:20 AM

RSSFeedBot RSSFeedBot is offline

I, Robot

About:

Join Date: Jul 2008

Posts: 10,117

Join Date: Jul 2008

Marketplace reputation 0% (0)

CPD Points: 1

Thanks: 0

Thanked 19 Times in 19 Posts

PSivida Announces New Safety And Efficacy Data From Phase 3 Study Of ILUVIEN(R) In Diabetic Macular Edema

Podiatry Arena members do not see these ads

pSivida Corp. (NASDAQ: PSDV)(ASX: PVA), a leader in developing sustained release, drug delivery products for treatment of back-of-the-eye diseases, today announced the presentation of new data from the completed 36-month FAME? Study of ILUVIEN for the treatment of Diabetic Macular Edema (DME) at the 2011 ARVO Annual Meeting. The new data, presented by Dr. Andrew N...

More...

Sponsored Links

« Previous Thread | Next Thread »

Thread Tools
Show Printable Version Email this Page
Display Modes
Linear Mode Switch to Hybrid Mode Switch to Threaded Mode

Posting Rules
You may not post new threads You may not post replies You may not post attachments You may not edit your posts	vB code is On Smilies are On [IMG] code is On HTML code is On

Forum Jump

Translate This Page

Similar Threads

Thread	Thread Starter	Forum	Replies	Last Post
Horizon Pharma, Inc. Announces Results Of Phase 3 Study Of LODOTRA® Demonstrate 12-Month Sustained Efficacy And Safety In Rheumatoid Arthritis	RSSFeedBot	Latest Rheumatology News	0	27th July 2010 04:30 AM
Tranzyme Pharma Announces Positive Results From Phase 2 Study Of Oral TZP-102 (Ghrelin Agonist) In Patients With Diabetic Gastroparesis	RSSFeedBot	Latest Diabetes Medicine Research & News	0	1st July 2010 04:40 AM
pSivida Announces Submission Of NDA To FDA For An Ophthalmic Product For Diabetic Macular Edema	RSSFeedBot	Latest Diabetes Medicine Research & News	0	1st July 2010 03:20 AM
Diabetic macular edema: Ranibizumab injections plus laser therapy results in dramatic visual improvement	RSSFeedBot	Latest Diabetes Medicine Research & News	0	27th April 2010 09:40 AM
CrystalGenomics Announces Positive Phase IIa Results For Osteoarthritis Study Of CG100649	RSSFeedBot	Latest Rheumatology News	0	23rd December 2008 05:30 AM

New To Site?	Need Help?
Register to Participate View Forum Leaders Contact Us	Frequently Asked Questions Did you forget your password? Mark Forums Read

Finding your way around:

Browse the forums.

Search the site.

Browse the tags.

Search the tags.

All times are GMT -7. The time now is 12:15 PM.

User Name		Remember Me?
Password